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background: The results of studies comparing the clinical efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve 
replacement (AVR) in low to intermediate risk patients are not yet available.
methods:  We compared outcomes in patients undergoing TAVR with low Society for Thoracic Surgery (STS) score but deemed inoperable for 
technical reasons versus AVR with similar STS risk score. The primary outcome was a composite of in-hospital death, myocardial infarction, stroke, 
and major vascular complications independently adjudicated using the Valve Academic Research Consortium definitions.
results: The TAVR (n=35) and AVR (n=37) groups were similar in regard to their mean STS Score (4.24 vs. 4.84, p=0.26). Reasons for inoperability 
were porcelain aorta (n=18), prior radiation to chest (n=7), prior CABG with risk of damaging graft (n=8), and other (n=2). There were no significant 
differences between the two groups in the composite endpoint (RR 0.74, 95%CI 0.32-1.73). TAVR patients had a significantly shorter length of stay 
(6.6 vs. 16.3 days p<0.005).
conclusions: Outcomes of TAVR in patients with low to intermediate STS risk score deemed technically inoperable are comparable to surgical AVR 
with similar STS risk score, but results in shorter hospital stays. Our results suggest that TAVR may become an established treatment for patients with 
intermediate surgical risk.
BASELINE DEMOGRAPHICS TAVR (n=35) AVR (n=37) P Value
Mean Age (Years +/-SD) 77.2 (+/-8.8) 81.7 (+/-7.7) 0.0249
Male 21 (60%) 20 (54%) 0.8869
Mean STS Score (+/-SD) 4.24 (+/-2.3) 4.84 (+/-2.2) 0.2603
Coronary Artery Disease 24 (69%) 12 (32%) 0.0047
Diabetes 9 (26%) 18 (49%) 0.1583
Prior MI 8 (23%) 4 (11%) 0.2917
Cerebrovascular Accident 7 (20%) 6 (16%) 0.9119
Peripheral Vascular Disease 15 (43%) 6 (16%) 0.026
PERI-PROCEDURAL OUTCOMES* TAVR (n=35) AVR (n=37) Relative Risk (95% CI; P value)
Hospital Length of Stay 6.6 (+/-4.6) 16.3 (+/-18.5) P=0.005
Composite Endpoint ** 7 (20%) 10 (26%) 0.74 (0.32 to 1.73; p=0.49)
Mortality 1 (3%) 2 (5%) 0.53 (0.05 to 5.57; p=0.60)
Myocardial Infarction 0 (0%) 3 (8%) 0.15 (0.008 to 2.82; p=0.21)
Stroke 1 (3%) 1 (3%) 1.06 (0.07 to 16.3; p=0.97)
Major Vascular Complication 5 (14%) 4 (10%) 1.32 (0.39 to 4.53; p=0.66)
* Independently adjudicated using VARC criteria
** Composite of mortality, myocardial infarction, stroke, and major vascular complications
